High hydrostatic pressure treatment generates inactivated mammalian tumor cells with immunogeneic features

Journal of Immunotoxicology

Volumn 7, Issue 3, 2010, Pages 194-204

  Weiss, E M ^a   Meister, S ^a,b   Janko, C ^a   Ebel, N ^a   Schlcker, E ^a   Meyer Pittroff, R ^c   Fietkau, R ^a   Herrmann, M ^a   Gaipl, U S ^a   Frey, B ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Apoptosis; Cell death; High hydrostatic pressure; Immunogenicity; Inactivation; Necrosis; Tumor vaccines

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; B LYMPHOCYTE; BURKITT LYMPHOMA; CANCER IMMUNIZATION; CELL DEATH; CELL NUCLEUS; CELL PROLIFERATION; CELL STRAIN; CELL STRAIN B16 F10; CELL STRAIN CT26; CELL STRAIN MCF 7; COLON ADENOCARCINOMA; COLON CARCINOMA; CONTROLLED STUDY; DNA CONTENT; DNA DEGRADATION; FEMALE; FLOW CYTOMETRY; FREEZE THAWING; GENE INACTIVATION; HUMAN; HUMAN CELL; HYDROSTATIC PRESSURE; IMMUNOGENETICS; IMMUNOGENICITY; ISOGRAFT; MAMMAL CELL; MELANOMA B16; MELANOMA CELL; NONHUMAN; PRIORITY JOURNAL; RAJI CELL; TUMOR CELL; XENOGRAFT;

ANIMALS; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CANCER VACCINES; CELL CULTURE TECHNIQUES; COLORECTAL NEOPLASMS; DNA FRAGMENTATION; FEMALE; HISTOCOMPATIBILITY ANTIGENS; HUMANS; HYDROSTATIC PRESSURE; IMMUNITY, HUMORAL; MELANOMA, EXPERIMENTAL; MICE; NEOPLASM TRANSPLANTATION; NEOPLASTIC STEM CELLS;

MAMMALIA;

EID: 77954934585     PISSN: 1547691X     EISSN: 1547691X     Source Type: Journal    
DOI: 10.3109/15476911003657414     Document Type: Article

References (61)

1. Aertsen, A., Meersman, F., Hendrickx, M. E., Vogel, R. F., and Michiels, C. W. 2009. Biotechnology under high pressure: Applications and implications. Trends Biotechnol. 27:434-441.
2. Amato, R. J. 2003. Vaccine therapy for renal cell carcinoma. Rev. Urol. 5:65-71.
3. Apetoh, L., Tesniere, A., Ghiringhelli, F., Kroemer, G., and Zitvogel, L. 2008. Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anti-cancer therapies. Cancer Res. 68:4026-4030.
4. Apte, R. N., and Voronov, E. 2008. Is interleukin-1 a good or bad 'guy' in tumor immunobiology and immunotherapy? Immunol. Rev. 222:222-241.
5. Balny, C. 1999. High-pressure enzyme kinetics. In Advances in High-Pressure Bioscience and Biotechnology (Ludwig, H., Ed.), Berlin: Springer Verlag, pp. 261-266.
6. Balny, C., Hayashi, R., Heremans, K., and Masson, P. (Eds.) 1992. High-Pressure and Biotechnology, Montrouge: Editions John Libbey Eurotext Ltd.
7. Balny, C., Masson, P., and Heremans, K. 2002. High-pressure effects on biological macromolecules: From structural changes to alteration of cellular processes. Biochim. Biophys. Acta 1595:3-10.
8. Bocchia, M., Bront, V, Colombo, M. P., Dd Vincentiis, A., Di Nicola, M., Forni, G., Lanata, L., Lemoli, R. M., Massaia, M., Rondelli, D., Zanon, P., and Tura, S. 2000. Anti-tumor vaccination: Where we stand. Haematologica 85:1172-1206.
9. Boonyaratanakornkit, B. B., Park, C. B., and Clark, D. S. 2002. Pressure effects on intra-and intermolecular interactions within proteins. Biochim. Biophys. Acta 1595:235-249.
10. Cheftel, J. C. 1992. Effects of high hydrostatic pressure on food constituents: An overview. In High-Pressure and Biotechnology (Balny, C., Hayashi, R., Heremans, K., and Masson, P., Eds.), Montrouge: INSERM/John Libbey Eurotext Ltd., pp. 195-209.
11. Chen, X., Chang, C. H., and Goldenberg, D. M. 2009. Novel strategies for improved cancer vaccines. Expert Rev. Vaccines 8:567-576.
12. Copier, J., Ward, S., and Dalgleish, A. 2007. Cell based cancer vaccines: Regulatory and commercial development. Vaccine 25(S2):B35-46.
13. De Gruijl, T. D., Van den Eertwegh, A. J., Pinedo, H. M., and Scheper, R. J. 2008. Whole-cell cancer vaccination: From autologous to allogeneic tumor-and dendritic cell-based vaccines. Cancer Immunol. Immunother. 57:1569-1577.
14. Diehl, P., Schauwecker, J., Mittelmeier, W., and Schmitt, M. 2008. High hydrostatic pressure, a novel approach in orthopedic surgical oncology to disinfect bone, tendons and cartilage. Anticancer Res. 28:3877-3883.
15. Diehl, P., Schmitt, M., Bluemelhuber, G., Frey, B., Van Laak, S., Fischer, S., Muehlenweg, B., Meyer-Pittroff, R., Gollwitzer, H., and Mittelmeier, W. 2003. Induction of tumor cell death by high hydrostatic pressure as a novel supporting technique in orthopedic surgery. Oncol. Rep. 10: 1851-1855.
16. Dillman, R. O., Depriest, C., Deleon, C., Barth, N. M., Schwartzberg, L. S., Beutel, L. D., Schiltz, P. M., and Nayak, S. K. 2007. Patient-specific vaccines derived from autologous tumor cell lines as active specific immunotherapy: Results of exploratory Phase I/II trials in patients with metastatic melanoma. Cancer Biother. Radiopharm. 22:309-321.
17. Dubins, D. N., Lee, A., Macgregor, R. B., Jr., and Chalikian, T. V. 2001. On the stability of double stranded nucleic acids. J. Am. Chem. Soc. 123: 9254-9259.
18. Elstein, K. H., and Zucker, R. M. 1994. Comparison of cellular and nuclear flow cytometric techniques for discriminating apoptotic sub-populations. Exp. Cell Res. 211:322-331.
19. Esche, C., Shurin, M. R., and Lotze, M. T. 1999. The use of dendritic cells for cancer vaccination. Curr. Opin. Mol. Ther. 1:72-81.
20. Franz, S., Herrmann, K., Furnrohr, B. G., Sheriff, A., Frey, B., Gaipl, U. S., Voll, R. E., Kalden, J. R., Jack, H. M., and Herrmann, M. 2007. After shrinkage apoptotic cells expose internal membrane-derived epitopes on their plasma membranes. Cell Death Differ. 14:733-742.
21. Frey, B., Franz, S., Sheriff, A., Korn, A., Bluemelhuber, G., Gaipl, U. S., Voll, R. E., Meyer-Pittroff, R., and Herrmann, M. 2004. Hydrostatic pressure induced death of mammalian cells engages pathways related to apoptosis or necrosis. Cell. Mol. Biol. (Noisy-le-grand) 50:459-467.
22. Frey, B., Janko, C., Ebel, N., Meister, S., Schlucker, E., Meyer-Pittroff, R., Fietkau, R., Herrmann, M., and Gaipl, U. S. 2008. Cells under pressure-treatment of eukaryotic cells with high hydrostatic pressure, from physiologic aspects to pressure-induced cell death. Curr. Med. Chem. 15:2329-2336.
23. Frey, B., Schildkopf, P., Rodel, F., Weiss, E. M., Munoz, L. E., Herrmann, M., Fietkau, R., and Gaipl, U. S. 2009. Annexin A5 renders dead tumor cells immunogenic-implications for multimodal cancer therapies. J. Immunotoxicol. 6:209-216.
24. Gaipl, U. S., Beyer, T. D., Baumann, I., Voll, R. E., Stach, C. M., Heyder, P., Kalden, J. R., Manfredi, A., and Herrmann, M. 2003a. Exposure of anionic phospholipids serves as anti-inflammatory and immunosuppressive signal-implications for anti-phospholipid syndrome and systemic lupus erythematosus. Immunobiology 207:73-81.
25. Gaipl, U. S., Brunner, J., Beyer, T. D., Voll, R. E., Kalden, J. R., and Herrmann, M. 2003b. Disposal of dying cells: A balancing act between infection and autoimmunity. Arthritis Rheum. 48:6-11.
26. Gaipl, U. S., Munoz, L. E., Rodel, F., Pausch, F., Frey, B., Brachvogel, B., Von der Mark, K., and Poschl, E. 2007. Modulation of the immune system by dying cells and the phosphatidylserine-ligand Annexin A5. Autoimmunity 40:254-259. (Pubitemid 46845517)
27. Gallucci, S., and Matzinger, P. 2001. Danger signals: SOS to the immune system. Curr. Opin. Immunol. 13:114-119.
28. Hacker, G. 2000. The morphology of apoptosis. Cell Tissue Res. 301:5-17.
29. Heden, C. G. 1964. Effects of hydrostatic pressure on microbial systems. Bacteriol. Rev. 28:14-29.
30. Heden, C. G., and Rupprecht, A. 1966. Semi-conductivity of dried oriented DNA. Acta Chem. Scand. 20:583-585.
31. Jocham, D., Richter, A., Hoffmann, L., Iwig, K., Fahlenkamp, D., Zakrzewski, G., Schmitt, E., Dannenberg, T., Lehmacher, W., Von Wietersheim, J.and Doehn, C. 2004. Adjuvant autologous renal tumor cell vaccine and risk of tumor progression in patients with renal-cell carcinoma after radical nephrectomy: Phase III randomized controlled trial. Lancet 363: 594-599.
32. Kepp, O., Tesniere, A., Schlemmer, F., Michaud, M., Senovilla, L., Zitvogel, L., and Kroemer, G. 2009. Immunogenic cell death modalities and their impact on cancer treatment. Apoptosis 14:364-375.
33. Korn, A., Frey, B., Sheriff, A., Gaipl, U. S., Franz, S., Meyer-Pittroff, R., Bluemelhuberh, G., and Herrmann, M. 2004. High hydrostatic pressure-inactivated human tumor cells preserve their immunogenicity. Cell. Mol. Biol. (Noisy-le-grand) 50:469-477.
34. Kroemer, G., Galluzzi, L., Van den Abeele, P., Abrams, J., Alnemri, E. S., Baehrecke, E. H., Blagosklonny, M. V., El-Deiry, W. S., Golstein, P., Green, D. R., Hengartner, M., Knight, R. A., Kumar, S., Lipton, S. A., Malorni, W., Nunez, G., Peter, M. E., Tschopp, J., Yuan, J., Piacentini, M., Zhivotovsky, B., and Melino, G. 2009. Classification of cell death: Recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ. 16:3-11.
35. Krysko, D. V., D'Herde, K., and Van den Abeele P., 2006. Clearance of apop-totic and necrotic cells and its immunological consequences. Apoptosis 11:1709-1726.
36. Macgregor, R. B. 2002. The interactions of nucleic acids at elevated hydrostatic pressure. Biochim. Biophys. Acta 1595:266-276.
37. Masson, P., Tonello, C., and Balny, C. 2001. High-pressure biotechnology in medicine and pharmaceutical science. J. Biomed. Biotechnol. 1:85-88.
38. Matzinger, P. 1994. Tolerance, danger, and the extended family. Annu. Rev. Immunol. 12:991-1045.
39. Meyer-Pittroff, R., Behrendt, H., and Ring, J. 2006. Specific immunomodulation and therapy by means of high-pressure-treated allergens. High Pressure Res. 26:1-5.
40. Moingeon, P., De Taisne, C., and Almond, J. 2002. Delivery technologies for human vaccines. Br. Med. Bull. 62:29-44.
41. Munoz, L. E., Frey, B., Pausch, F., Baum, W., Mueller, R. B., Brachvogel, B., Poschl, E., Rodel, F., Von der Mark, K., Herrmann, M., and Gaipl, U. S. 2007. The role of Annexin A5 in the modulation of the immune response against dying and dead cells. Curr. Med. Chem. 14:271-277.
42. Nicoletti, I., Migliorati, G., Pagliacci, M. C., Grignani, F., and Riccardi, C. 1991. A rapid and simple method for measuring thymocyte apoptosis by propid-ium iodide staining and flow cytometry. J. Immunol. Meth. 139:271-279.
43. Ott, O. J., Rodel, C., Weiss, C., Wittlinger, M., St., Krause, F., Dunst, J., Fietkau, R., and Sauer, R. 2009. Radiochemotherapy for bladder cancer. Clin. Oncol. (R. Coll. Radiol.) 21:557-565.
44. Patterson, M. F. 2005. Microbiology of pressure-treated foods. J. Appl. Microbiol. 98:1400-1409.
45. Paukovits, P., Himmler, G., and Loibner, H. 2004. Immunotherapy of malignant diseases-developments and prospects. Wien Med. Wochenschr. 154:235-241.
46. Rosenberg, S. A., Yang, J. C., and Restifo, N. P. 2004. Cancer immunotherapy: Moving beyond current vaccines. Nat. Med. 10:909-915.
47. Rosenblatt, J., and Avigan, D. 2008. Cellular immunotherapy for multiple myeloma. Best Pract. Res. Clin. Haematol. 21:559-577.
48. San Martin, M. F., Barbosa-Canovas, G. V, and Swanson, B. G. 2002. Food processing by high hydrostatic pressure. Crit. Rev. Food Sci. Nutr. 42: 627-645.
49. Shearer, A. E., and Kniel, K. E. 2009. High hydrostatic pressure for development of vaccines. J. Food Prot. 72:1500-1508.
50. Smeller, L. 2002. Pressure-temperature phase diagrams of biomolecules. Biochim. Biophys. Acta 1595:11-29.
51. Stach, C. M., Turnay, X., Voll, R. E., Kern, P. M., Kolowos, W., Beyer, T. D., Kalden, J. R., and Herrmann, M. 2000. Treatment with Annexin V increases immunogenicity of apoptotic human T-cells in Balb/c mice. Cell Death Differ. 7:911-915.
52. Tesniere, A., Apetoh, L., Ghiringhelli, F., Joza, N., Panaretakis, T., Kepp, O., Schlemmer, F., Zitvogel, L., and Kroemer, G. 2008. Immunogenic cancer cell death: A key-lock paradigm. Curr. Opin. Immunol. 20:504-511.
53. Umansky, V, Malyguine, A., and Shurin, M. 2009. New perspectives in cancer immunotherapy and immunomonitoring. Future Oncol. 5:941-944.
54. Vermes, I., Haanen, C., and Reutelingsperger, C. 2000. Flow cytometry of apoptotic cell death. J. Immunol. Meth. 243:167-190.
55. Vermes, I., Haanen, C., Steffens-Nakken, H., and Reutelingsperger, C. 1995. A novel assay for apoptosis. Flow cytometric detection of phosphatidylser-ine expression on early apoptotic cells using fluorescein-labeled Annexin V J. Immunol. Meth. 184:39-51.
56. Voll, R. E., Herrmann, M., Roth, E. A., Stach, C., Kalden, J. R., and Girkontaite, I. 1997. Immunosuppressive effects of apoptotic cells. Nature 390:350-351.
57. Winter, R. 2002. Synchrotron X-ray and neutron small-angle scattering of lyo-tropic lipid mesophases, model biomembranes, and proteins in solution at high pressure. Biochim. Biophys. Acta 1595:160-184.
58. Winter, R., and Dzwolak, W. 2004. Temperature-pressure configurational landscape of lipid bilayers and proteins. Cell. Mol. Biol. (Noisy-le-grand) 50:397-417.
59. Yannelli, J. R., Hirscowitz, E., and Wroblewski, J. M. 2003. Growth and functional reactivity of lymphocytes obtained from three anatomic compartments in patients with non-small-cell lung cancer (NSCLC). Cancer Biother. Radiopharm. 18:735-749.
60. Yannelli, J. R., and Wroblewski, J. M. 2004. On the road to a tumor cell vaccine: 20 years of cellular immunotherapy. Vaccine 23:97-113.
61. Yi, Q. 2003. Immunotherapy in multiple myeloma: Current strategies and future prospects. Expert Rev. Vaccines 2:391-398.